CBD for Eczema: What the Endocannabinoid System Has to Do With Atopic Dermatitis

Eczema -- atopic dermatitis -- is one of the most studied conditions in CBD skin research, and for a specific reason: atopic dermatitis involves documented dysfunction in the skin's endocannabinoid system that makes it particularly responsive to topical cannabinoid intervention. Understanding the ECS connection to eczema explains why CBD research in this area is among the most promising in dermatology.

The ECS Dysfunction in Atopic Dermatitis

Research has established that atopic dermatitis is associated with altered endocannabinoid system function in the skin. Studies have found reduced anandamide levels in eczema-affected skin compared to healthy skin, suggesting that ECS deficiency contributes to the inflammatory and barrier dysfunction that characterizes atopic dermatitis. If the skin's own endocannabinoid signaling is reduced in eczema, supplementing that signaling with topical CBD -- which both activates cannabinoid receptors and inhibits anandamide degradation through FAAH -- is a mechanistically rational intervention.

CBD's Multi-Mechanism Approach to Eczema

CB2 receptor activation: Reduces the Th2-skewed inflammatory cytokine production that drives atopic dermatitis -- specifically IL-4, IL-13, and IL-31, the cytokines targeted by the most expensive eczema biologics.

FAAH inhibition: Increases anandamide levels in eczema-affected skin, addressing the documented endocannabinoid deficiency and supporting ECS-mediated barrier repair.

TRPV1 modulation: Reduces the itch signaling that is among the most debilitating symptoms of atopic dermatitis. Itch drives scratching, which further disrupts the barrier, creating the itch-scratch-barrier damage cycle that maintains chronic eczema.

The Clinical Evidence

A 2019 study in Clinical Therapeutics on topical CBD for atopic dermatitis found significant improvements in skin hydration, TEWL, and subjective itch and sleep quality scores over 20 weeks of twice-daily application. The researchers concluded that topical cannabidiol is a well-tolerated and effective add-on therapy for atopic dermatitis. The results were achieved without the side effects associated with topical corticosteroids.

Why Restore Is Formulated for Conditions Like Eczema

Restore's wagyu tallow base provides the barrier structural lipids that eczema skin is chronically deficient in -- directly addressing the physical barrier dysfunction alongside CBD's ECS-mediated effects. The CLA in the tallow base provides additional anti-inflammatory activity through the prostaglandin pathway that CBD does not address. The absence of preservatives, seed oils, and synthetic emulsifiers removes the topical inflammatory inputs that conventional eczema moisturizers impose on already-compromised skin.

Be among the first to experience Golden Tallow Restore. Join the early access list at early.goldentallow.com and explore the full Golden Tallow lineup at goldentallow.com. 🤍